Division of Hematology/Oncology

Faculty

faculty photo

Jakub Svoboda, MD

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Data Safety and Monitoring Committee , Abramson Cancer Center
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-614-1846
Fax: 215-615-5888
Education:
B.A. (Biology)
Mercyhurst College (Erie, PA), 1994.
M.D. (Medicine)
Yale University School of Medicine, 2000.
Post-Graduate Training
Intern in Medicine, University of Pennsylvania, 2000-2001.
Resident in Medicine, University of Pennsylvania, 2001-2003.
Fellow in Hematology-Oncology, University of Pennsylvania, 2003-2006.
Certifications
American Board of Internal Medicine, 2003.
American Board of Internal Medicine (Medical Oncology), 2006.
American Board of Internal Medicine (Hematology), 2007.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Howlett Christina, Snedecor Sonya J, Landsburg Daniel J, Svoboda Jakub, Chong Elise A, Schuster Stephen J, Nasta Sunita Dwivedy, Feldman Tatyana, Rago Allison, Walsh Kristy M, Weber Scott, Goy Andre, Mato Anthony: Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. British Journal of Haematology 170(4): 504-14, Aug 2015.

Huntington Scott F, Svoboda Jakub, Doshi Jalpa A: Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal of Clinical Oncology 33(13): 1467-74, May 2015.

Shah Nirav N, Kucharczuk Colleen R, Mitra Nandita, Hirsh Rebecca, Svoboda Jakub, Porter David, Loren Alison, Frey Noelle, Schapira Marilyn M: Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes. Biology of Blood and Marrow Transplantation May 2015 Notes: [Epub ahead of print]

Mato Anthony R, Foon Kenneth A, Feldman Tatyana, Schuster Stephen J, Svoboda Jakub, Chow Kar Fai, Valentinetti Marisa, Mrkulic Mary, Azzollini Kelly, Gadaleta Gabriella, Bhattacharyya Pritish K, Zenreich Joshua, Pascual Lauren-Nicole, Yannotti Kara, Kdiry Sabrina, Howlett Christina, Strelec Lauren, Porter David, Bejot Coleen, Goy André: Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. American Journal of Hematology Feb 2015 Notes: [Epub ahead of print]

Chong Elise A, Ahmadi Tahamtan, Aqui Nicole, Svoboda Jakub, Nasta Sunita D, Mato Anthony R, Walsh Kristy M, Schuster Stephen J: Combination of lenalidomide and rituximab overcomes rituximab-resistance in patients with indolent B-cell and mantle cell lymphomas. Clinical Cancer Research Jan 2015.

Huntington Scott F, Nasta Sunita D, Schuster Stephen J, Doshi Jalpa A, Svoboda Jakub: Utility of interim and end-of-treatment FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma Page: 1-19, Jan 2015 Notes: [Epub ahead of print]

Ruan, J., Martin, P., Shah, B., Schuster, S.J., Smith, S.M., Furman, R.R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., Katz, O., Coleman, M., and Leonard, J.P.: Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma. New England Journal of Medicine 2015 Notes: Accepted for publication 6/25/2015.

Marlise R. Luskin, Alex Ganetsky, Daniel Landsburg, Alison W. Loren, David Porter, Sunita Nasta, Jakub Svoboda, Selina Luger, Noelle Frey.: Nelarabine, cyclosphosphamide, and etoposide (NCE) for adults with relapsed T acute lymphoblastic leukemia and lymphoma. British Journal of Haematology 2015 Notes: Accepted for publication 8/13/2015.

Shah Nirav N, Harrison Neil, Stonecypher Mark, Frank Dale, Amorosa Valerianna, Svoboda Jakub: Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis. Clinical lymphoma, myeloma & leukemia 14(5): e157-60, Oct 2014.

Nagle Sarah J, Chong Elise A, Chekol Seble, Shah Nirav N, Nasta Sunita D, Glatstein Eli, Plastaras John P, Torigian Drew A, Schuster Stephen J, Svoboda Jakub: The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. Cancer Medicine 4(1): 7-15, Sep 2014.

back to top
Last updated: 08/28/2015
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter